A study of "Tocilizumab treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants". Chauvin et al
Published: 24 January 2023| Version 1 | DOI: 10.17632/krh7cy99wg.1
CAMILLE CHAUVIN, LAURINE LEVILLAYER, MATHILDE ROUMIER, HUBERT NIELLY, CLAUDE ROTH, ANUPAMA KARNAM, SRINIVASA REDDY BONAM, ANNE BOURGARIT-DURAND, CLEMENT DUBOST, AURORE BOUSQUET, SEBASTIEN LE BUREL, RAPHAELE MESTIRI, DAMIEN SENE, JORIS GALLAND, MARC VASSE, MATHIEU GROH, MATHILDE LE MARCHAND, CAMILLE VASSORD-DANG, Jean-Francois Gautier, NHAN PHAM-THI, CHRISTIANE VERNY, BRUNO PITARD, Cyril Planchais, HUGO MOUQUET, RICHARD PAUL, ETIENNE SIMON-LORIERE, jagadeesh Bayry, LAURENT GILARDIN, ANAVAJ SAKUNTABHAI
Supplementary Dataset for the manuscript "Tocilizumab treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants". Description of each patient according to disease severity and treatment. 55 out of 69 patients were recruited during the first COVID-19 wave while 14 patients were recruited during the second/third wave of COVID-19.
Institut Pasteur, INSERM, Sorbonne Universite, Universite de Paris